Are We Making Any Progress in Treatment and Attitudes?

Are We Making Any Progress in Treatment and Attitudes?

Publication date: Mar 24, 2020

Berger went on to discuss the 1919 interpretation of the Harrison Act of 1915-that keeping an opioid dependent patient -comfortable by maintaining his customary [opioid] use was not a prescription, within the meaning of the law . . . .” As a result, physicians became targets for arrest and imprisonment for prescribing narcotics to control withdrawal symptoms in attempt to make their patients comfortable.

Other off-label medications also were used for reducing opioid withdrawal symptoms, including the use of clonidine for opioid withdrawal along with other non-opioid medications.

Progress has been more evident during these more recent 50 years, moving us further away from the 1919 decisions that made it illegal to provide medical help to people with an opioid addiction.

In addition to these maintenance approaches to treatment, aids for managing the symptoms of opioid discontinuation, such as clonidine and most recently lofexidine, also became available.

However, along with the more humane treatments for addiction, an opposing trend began from the pharmaceutical industry to increase sales of opioids for managing -insufficiently treated” chronic pain syndromes.

In Ohio and in a recent Oklahoma case, the judge stated that one company -engaged in false and misleading marketing of both their drugs and opioids generally, and the law makes clear that such conduct is more than enough to serve as the act or omission necessary to establish the first element of Oklahoma’s public nuisance law. “

Concepts Keywords
Addiction Naltrexone
Agonist Buprenorphine
Alcohol Lofexidine
Alcoholism Opioid use disorder
Aversive Chronic pain conditions
Benign Pain
Buprenorphine Opioid withdrawal symptoms
Chlorpromazine Financial settlements pharmaceutical
Chronic Pain Pharmaceutical advertising campaign
Clonidine Public nuisance law
Cold Turkey Ketones
Criminal Justice Euphoriants
Drug Czar Drug rehabilitation
Early Edition Drugs
Epidemic Morphinans
Evolution RTT
FDA Chemical compounds
Fibromyalgia Opioids
French
Jerome
Methadone
Naltrexone
Narcotics
Neurobiology
Ohio
Oklahoma
Opioid
Opioid Addiction
Opioid Withdrawal
Opioids
Oxycontin
Pain
Partial Agonist
Peripheral Neuropathies
Pharmaceutical Companies
Pharmaceutical Industry
Physician
Public Nuisance
Social Stigma
Stimulants
Withdrawal Symptoms

Semantics

Type Source Name
disease MESH development
drug DRUGBANK Naltrexone
drug DRUGBANK Methadone
disease MESH opioid addiction
disease MESH fibromyalgia
disease MESH backaches
disease MESH peripheral neuropathies
drug DRUGBANK Clonidine
disease MESH chronic pain
drug DRUGBANK Chlorpromazine
disease MESH withdrawal symptoms
disease MESH Narcotic Addiction
pathway KEGG Alcoholism
disease MESH Alcoholism
disease MESH syndromes
drug DRUGBANK Ethanol
disease MESH substance use disorders
disease MESH social stigma
drug DRUGBANK Lofexidine
disease MESH aids
drug DRUGBANK Buprenorphine
disease MESH death

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *